Financial Performance and Capital Needs - The company has incurred significant operating losses since its inception, with an accumulated deficit of approximately $154.6 million as of December 31, 2025[207]. - The company expects to continue incurring substantial operating losses over the next several years as it develops and seeks regulatory approval for its product candidate, elraglusib[207]. - As of December 31, 2025, the company had approximately $13.2 million in cash and cash equivalents, with working capital of approximately $7.9 million, which is projected to be insufficient beyond July 2026[211]. - The company anticipates needing substantial additional capital to finance its operations and may seek funding through public or private equity, debt financings, or strategic partnerships[212][213]. - The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern[214]. Product Development and Regulatory Risks - The company relies entirely on the success of elraglusib, which is currently in Phase 2 clinical development for mPDAC, making its business highly dependent on this single product candidate[218]. - The company faces significant risks in obtaining regulatory approvals, which are essential for the commercialization of elraglusib, and any delays could materially harm its business[221][222]. - The company has no approved products on the market and may never achieve profitability if it fails to successfully develop and commercialize elraglusib[221]. - The company acknowledges that the drug development process is lengthy, expensive, and fraught with uncertainty, with a high historical failure rate for product candidates in the biopharmaceutical industry[226]. - The company has not yet demonstrated an ability to overcome the risks and uncertainties associated with biopharmaceutical product development, which complicates its ability to predict future expenses and profitability[210]. - Elraglusib has received Fast Track designation from the FDA for the treatment of pancreatic cancer, which may facilitate the review process but does not guarantee marketing approval[247]. - The company has not yet initiated or completed a Phase 3 clinical trial, which is critical for obtaining FDA approval for elraglusib or any future product candidates[239]. - The company may face significant setbacks in clinical development despite promising early results, as many product candidates fail in later trials[228]. - Enrollment delays in clinical trials could materially affect the company's financial condition and development timelines[238]. - The company may need to conduct additional preclinical studies or clinical trials based on negative or inconclusive results, leading to increased operating expenses and delays[229]. Manufacturing and Supply Chain Challenges - The company relies on a single manufacturer in China for elraglusib's drug substance, and geopolitical factors could impact supply and costs[266]. - The company currently has a sole source manufacturer for the drug substance of elraglusib, which poses risks of supply disruption[278]. - There are no long-term supply agreements in place with suppliers, which could delay clinical trials if supplies are not sourced timely[271]. - The company may face challenges in obtaining regulatory approvals for manufacturing facilities, which could significantly affect product development[270]. - Geopolitical tensions with China could impact the company's ability to conduct clinical trials if relying on Chinese vendors[279]. - The company has limited control over third-party manufacturers' compliance with quality standards, which could affect product quality[269]. - The company is dependent on third parties for conducting clinical trials, which could lead to delays if these parties do not meet their obligations[273]. Intellectual Property Risks - Intellectual property rights may not be enforceable in certain foreign jurisdictions, potentially allowing competitors to exploit the company's innovations[281]. - The company has filed several new composition of matter patent applications for elraglusib, which could expire in 2038, with potential for patent term extensions[283]. - Patent applications in the pharmaceutical and biotechnology sectors may be limited in scope, potentially reducing competitive protection[285]. - The company faces risks of patent expirations, which could diminish competitive advantages and product value[286]. - Trade secrets and proprietary know-how are critical for maintaining competitive position, but their protection is uncertain[287]. - Intellectual property claims may not sufficiently prevent competitors from developing similar products, impacting financial performance[288]. - The company may incur significant costs and time in addressing intellectual property disputes, which could adversely affect business operations[289]. - Changes in patent laws could weaken the company's ability to protect its intellectual property and affect its commercial value[293]. - Patent terms are limited to generally 20 years, which may not provide adequate protection for product candidates like elraglusib[294]. - The company may face claims challenging the inventorship or ownership of its patents, which could result in loss of valuable intellectual property rights[296]. - Third-party intellectual property rights could hinder the commercialization of current or future technologies, requiring potential litigation or licensing[299]. - Infringement claims could lead to substantial damages or force the company to abandon technologies, impacting financial condition and operations[300]. - The company may face claims regarding the wrongful use or disclosure of trade secrets by employees or consultants, which could lead to litigation and substantial costs[301]. - Intellectual property rights may be subject to federal regulations due to government funding, potentially limiting exclusive rights and requiring compliance with reporting requirements[303]. - The U.S. government may have rights to inventions developed under government-funded programs, including the ability to require licensing to third parties if commercialization steps are inadequate[304]. Compliance and Operational Risks - Compliance with healthcare laws and regulations may increase operational costs and expose the company to significant penalties if found in violation[305]. - Strategic transactions, such as acquisitions or partnerships, may incur non-recurring charges and increase near- and long-term expenditures, posing integration challenges[308]. - Cybersecurity incidents could disrupt development programs and compromise sensitive information, potentially leading to significant costs and reputational damage[311]. - The company relies on third-party vendors for IT infrastructure, which may expose it to vulnerabilities if those vendors fail to protect confidential information[313]. - Non-compliance with health privacy and data protection laws could result in government enforcement actions, private litigation, and damage to the company's reputation[315]. - The evolving legal framework around privacy issues may impose new obligations and restrictions on data collection and usage, impacting operational capabilities[318]. - Disruptions at the FDA and other government agencies due to funding shortages and personnel changes could delay the approval and commercialization of new products, negatively impacting the company's business[319]. - The FDA postponed most inspections during the COVID-19 pandemic, and future global health concerns may lead to similar delays, significantly affecting the company's regulatory submissions[320]. - The company's lead drug development program, elraglusib, will be reviewed by the FDA's Center for Drug Evaluation and Research (CDER), which is known for demanding high-quality clinical research[321]. - The company lacks in-house expertise in drug approvals and may rely on consultants, which poses risks of delays and increased expenses in the drug approval process[322]. Stock and Corporate Governance Risks - Approximately 43% of the company's common stock is held by funds affiliated with the chairman, potentially limiting other stockholders' influence and creating conflicts of interest[324]. - The company has never declared or paid cash dividends and does not intend to do so in the foreseeable future, relying on stock price appreciation for returns[331]. - The trading price of the company's common stock is likely to be highly volatile, influenced by clinical trial results, regulatory approvals, and market conditions[329]. - The company may face challenges in maintaining compliance with Nasdaq listing requirements, which could lead to delisting and negatively impact stock price[327]. - The company's amended and restated bylaws contain provisions that could make mergers or proxy contests difficult, potentially depressing stock value[332]. - The company is subject to anti-takeover provisions under Delaware law, which may limit business combinations with significant stockholders[335]. - The company faces significant risks due to unstable market and economic conditions, which may adversely affect its ability to raise funds and could lead to operational delays[338]. - The company is at risk of declining stock price and trading volume if analysts downgrade its stock or cease coverage, impacting investor interest[339]. - The company must maintain effective internal control over financial reporting to ensure accurate financial statements; failure to do so could lead to a decline in stock price and investor confidence[340]. - If the company cannot demonstrate effective internal controls, it may face sanctions from regulatory authorities, which could restrict future access to capital markets[341]. - The company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures[417].

Core Insights - Actuate Therapeutics is advancing elraglusib, a first-in-class GSK-3 inhibitor, targeting multiple difficult-to-treat cancers including mPDAC, melanoma, colorectal cancer, and sarcomas [1][11] - The company is focusing on a dual formulation strategy with both intravenous and oral versions of elraglusib, enhancing its commercial appeal and patient compliance [2][10] Pediatric Breakthroughs - Actuate reported promising phase 1 data from the Actuate-1902 trial involving 40 children and adolescents, achieving complete responses in relapsed/refractory metastatic Ewing sarcoma and neuroblastoma [3][4] - The FDA granted Rare Pediatric Disease Designation for elraglusib, making the company eligible for a Priority Review Voucher (PRV) upon approval of a New Drug Application [4][5] Value of PRVs - PRVs have been sold at premium prices, with recent transactions averaging between $150 million and $200 million, providing significant non-dilutive capital opportunities for small-cap companies like Actuate [6][10] - The PRV program incentivizes the development of treatments for rare pediatric diseases, potentially accelerating revenue generation for Actuate [5][6] RAS Inhibitor Strategy - Actuate is launching a research initiative to evaluate elraglusib in combination with emerging RAS-targeted therapies, addressing adaptive resistance seen in RAS-driven cancers [7][10] - The combination of elraglusib with RAS inhibitors could enhance treatment efficacy by overcoming resistance mechanisms and improving patient outcomes [8][10] Strategic Outlook - Actuate is entering a high-impact period with multiple catalysts, including positive pediatric data, an advancing oral formulation, and a new RAS combination program [10][12] - The potential monetization of a PRV could provide immediate capital, while ongoing research opens avenues for broader market opportunities and collaborations [10][12]

Core Insights - Actuate Therapeutics, Inc. has launched an expanded research initiative to evaluate the combination of its GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies to enhance treatment for difficult-to-treat cancers [1][2] Group 1: Research Initiative - The initiative aims to address adaptive resistance mechanisms in RAS-targeted therapies, which are significant barriers to achieving durable responses in patients [2] - GSK-3β inhibition may enhance RAS-targeted therapies by suppressing downstream survival signaling and resistance pathways, potentially improving clinical outcomes in RAS-driven cancers [2][6] Group 2: Elraglusib Overview - Elraglusib is a highly selective GSK-3β inhibitor with potential applications across various oncology indications, including pancreatic cancer, melanoma, colorectal cancer, and sarcoma [3] - The investigational drug has been administered to over 500 patients and is currently in a Phase 2 trial for metastatic pancreatic cancer [3] Group 3: Combination Strategy - The combination strategy aims to block proliferative signaling through RAS inhibition while disrupting tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic signaling [4] - The program will include in-vitro studies, in-vivo tumor regression and survival studies, and translational biomarker analysis, with initial data expected in Q2 2026 [5][6] Group 4: Future Development - The company is collaborating with leading academic institutions and potential industry partners to advance elraglusib as a foundational component of next-generation treatment paradigms for RAS-driven cancers [6] - Preclinical combination results are anticipated in the second half of 2026, which will inform future clinical development plans [8]

Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1] Company Overview - Actuate's lead investigational drug, elraglusib, is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments [4] - Elraglusib may also enhance anti-tumor immunity by regulating multiple immune checkpoints and immune cell functions [4] Upcoming Events - Dan Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference in Miami Beach, FL on March 10, 2026, at 8:25 a.m. ET [1] - A live webcast of the presentation will be available on Actuate's website, with a replay accessible for 30 days following the event [3]

Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers through the inhibition of GSK-3β, with a presentation scheduled at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 [1] Company Overview - Actuate Therapeutics is dedicated to creating therapies for high-impact cancers, with its lead investigational drug, elraglusib, targeting molecular pathways that promote tumor growth and resistance to conventional treatments [4] - Elraglusib functions as a GSK-3β inhibitor and may enhance anti-tumor immunity by regulating immune checkpoints and immune cell function [4] Presentation Details - Dan Schmitt, President & CEO of Actuate, will present at the Oppenheimer conference at 9:20 a.m. ET on February 26, 2026 [1] - A webcast of the presentation will be available, and a replay will be accessible on the company's website for 30 days following the event [2][3] - The management team will also conduct one-on-one meetings with investors during the conference [2]

Core Insights - Actuate Therapeutics plans to initiate a Phase 1/2 clinical program for elraglusib, an oral tablet formulation targeting advanced cancers, in the second half of 2026 [1][2] Group 1: Clinical Trial Details - The Phase 1 portion aims to determine the maximum tolerated dose (MTD) and assess dose-limiting toxicities (DLTs) of elraglusib tablets, while also investigating pharmacokinetics (PK) and preliminary anti-tumor activity [2] - The Phase 2 trial will focus on patients with refractory metastatic melanoma and other indications, building on previous encouraging results from a Phase 1 study where 5 out of 10 patients achieved disease control lasting 12 weeks or longer [2] - In the earlier Phase 1 study involving 67 patients, the median overall survival was reported at 9.9 months, with one patient achieving a complete response lasting over 6 years [2] Group 2: Drug Mechanism and Target Indications - Elraglusib targets glycogen synthase kinase-3 beta (GSK-3β), which is implicated in cancer progression, particularly in melanoma [3] - The drug may provide synergistic potential with existing therapies, such as BRAF and MEK inhibitors, and immune checkpoint inhibitors (ICIs) [3] - The company plans to include additional targeted histologies in the Phase 1/2 study, particularly select hematologic malignancies where GSK-3β inhibition has shown activity [4] Group 3: Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers [5] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional therapies [5][6]

Core Insights - Actuate Therapeutics is advancing the clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, having received Rare Pediatric Designations from the FDA for both indications [1][3] Study Overview - The Actuate-1902 trial is an open-label, multicenter phase 1/2 study involving 40 pediatric patients aged 3 to 21 with relapsed or refractory cancers, including Ewing sarcoma and neuroblastoma [2][8] - The primary goal of the phase 1 portion was to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of elraglusib, with initial evidence of anti-tumor activity observed [8] Clinical Results - The phase 1 trial showed clinical responses in relapsed/refractory Ewing sarcoma, with two Complete Metabolic Responses (CMRs) in patients and one Complete Response (CR) in a neuroblastoma patient [6][3] - Overall, clinical responses and disease control were observed in 15 out of 40 patients with difficult-to-treat pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecan [6][7] Future Plans - The company plans to initiate additional clinical trials in 2026 to expedite a registration pathway for elraglusib in Ewing sarcoma and potentially advance its use in neuroblastoma [4][3] - Collaborative development programs are being assessed with leading pediatric consortia and Key Opinion Leaders to align future studies with patient needs and regulatory expectations [3] Mechanism of Action - Elraglusib is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer therapies, potentially mediating anti-tumor immunity [12]

Core Viewpoint - Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system focuses on the consensus measure of EPS estimates from sell-side analysts, which reflects the changing earnings picture of a company [2]. - The Zacks Consensus Estimate for Actuate Therapeutics is projected at -$1.10 per share for the fiscal year ending December 2025, showing no year-over-year change, but estimates have increased by 0.9% over the past three months [9]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [5]. - Institutional investors' actions, driven by earnings revisions, lead to significant price movements in stocks [5]. Business Outlook - The upgrade in Zacks Rank for Actuate Therapeutics suggests an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively to this trend [6][11]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - Actuate Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10][11].

Core Insights - Actuate Therapeutics, Inc. announced that data from its Phase 2 study of elraglusib in metastatic pancreatic cancer will be presented at the 2026 ASCO GI Cancers Symposium [1] - The study evaluates elraglusib in combination with gemcitabine/nab-paclitaxel, a standard chemotherapy regimen for this type of cancer [1] Presentation Details - Oral Presentation: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma [2] - Date/Time: January 9, 2026, 4:15 PM-5:00 PM (PST) [2] - First Author: Devalingam Mahalingam, MD, PhD, Gastrointestinal Oncologist at Northwestern University [2] Poster Presentation - Title: Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with elraglusib and gemcitabine/nab-paclitaxel [3] - Date/Time: January 9, 2026, 11:30 AM-1:00 PM; 5:00 PM-6:00 PM (PST) [4] - First Author: Andrey Ugolkov, MD, PhD, Senior Director, Clinical Science at Actuate Therapeutics [4] Company Overview - Actuate Therapeutics is focused on developing therapies for high-impact, difficult-to-treat cancers [4] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting pathways involved in tumor growth and resistance to conventional therapies [4]

Core Insights - Actuate Therapeutics, Inc. announced promising results from a Phase II study of elraglusib, showing a median overall survival of 18.6 months and 40% of patients alive at 2 years [1][5][6] Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with elraglusib as its lead investigational drug targeting GSK-3β [8] Study Details - The Phase II study evaluated elraglusib in combination with platinum chemotherapy in patients with advanced, metastatic salivary gland cancers, including adenoid cystic carcinoma [3][7] - The study enrolled 32 patients, with a median progression-free survival of 6.4 months and 27% of patients progression-free at 1 year [5][11] Key Findings - Nuclear GSK-3β expression was significantly higher in responders (50%) compared to non-responders (2%), suggesting its potential as a biomarker for treatment response [3][11] - Among non-ACC patients receiving immune priming followed by cisplatin plus elraglusib, the response rate was 18%, with all responders showing elevated nuclear GSK-3β expression [4][6] Treatment Efficacy - The median overall survival for non-ACC patients was notably higher at 27.8 months, indicating a potential benefit of elraglusib in this subgroup [5] - The combination treatment was well tolerated, with no treatment-related deaths and a low discontinuation rate due to toxicity [11]